Can a multiple ascending dose study serve as an informative proof-of-concept study?

Area of Science:

• Clinical Pharmacology
• Drug Development Strategy
• Biostatistics

Background:

• Drug development is lengthy, expensive, and prone to high failure rates, particularly in Phase 2 and Phase 3 clinical trials.
• Current drug development costs are heavily influenced by the expenses associated with late-stage clinical trials.
• Improving the success rate of Phase 2 trials by obtaining more informative preclinical data can significantly reduce overall development costs.

Purpose of the Study:

• To propose a novel model-based multiple ascending dose (MAD) study design.
• To demonstrate that MAD studies can yield informative efficacy data in addition to safety data.
• To enable early proof-of-concept validation, thereby reducing drug development cycle time and costs.

Main Methods:

• Utilizing parametric models for longitudinal dose-response relationships.
• Incorporating models that describe the impact of dose titration on response variables.
• Applying a model-based approach to the design of multiple ascending dose (MAD) studies.

Main Results:

• The proposed MAD design provides essential safety information.
• The design generates valuable, early-stage efficacy data for specific endpoints and therapeutic areas.
• This approach allows for preliminary proof-of-concept assessment before Phase 2 trials.

Conclusions:

• A model-based MAD design can enhance early drug development by providing both safety and efficacy insights.
• This strategy can serve as an effective proof-of-concept study, informing decisions prior to Phase 2.
• Implementing this design may significantly shorten drug development timelines without escalating Phase 2 risks.